MB-HSPG@EC2602A(19379.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
MB-HSPG@EC2602A
19379.HK
News
View More

Top 5 HK Stock Gainers/Losers (>100B) (1.27)

MINIMAX-WP(00100) rose 26.48%, with a trading turnover 1.6 Billion HKD, and a year-to-date rose 195.9%. ZIJIN GOLD INTL(02259) rose 11.59%, with a trading turnover 3.1 Billion HKD, and a year-to-date rose 59.6%. HANSOH PHARMA(03692) fell 4.37%, with a trading turnover 420.6 Million HKD, and a year-to-date rose 6.7%. LAOPU GOLD(06181) fell 3.24%, with a trading turnover 1.4 Billion HKD, and a year-to-date rose 33%.

Top Gainers & Losers·
HK
00100
+10.68%
HK
02259
-7.87%
HK
02513
-0.71%
Top Gainers & Losers·
HK
00100
+10.68%
HK
02259
-7.87%
HK
02513
-0.71%

Hansoh Pharmaceutical to Raise HK$4.68 Billion via Zero-Coupon Convertible Bonds

Hansoh Pharmaceutical Group Company Limited plans to raise HK$4.68 billion through the issuance of zero-coupon convertible bonds due 2033. The bonds, convertible into approximately 81.5 million shares at an initial price of HK$57.39 per share, will be offered to professional investors in Hong Kong and outside the U.S. The net proceeds will be used as specified by the company, but completion is subject to certain conditions. The latest analyst rating for the stock is a Buy with a price target of HK$48.20.

Tip Ranks·
HK
03692
-3.16%
Tip Ranks·
HK
03692
-3.16%

China's Hansoh Pharmaceutical launches $600 million convertible bond, term sheet shows

China’s Hansoh Pharmaceutical Group is raising $600 million through a seven-year zero-coupon convertible bond. The bonds, due in 2033, have a 0% yield and are convertible at a premium of 47% to 52% over the reference share price. Proceeds will fund research, manufacturing facilities, and corporate purposes. Hansoh focuses on developing medicines for various diseases. Shares have increased by 11.5% this year. Morgan Stanley and Citigroup are the joint global coordinators for this bond issuance.

Reuters·
SH
562050
-2.79%
SZ
002907
-0.40%
HK
03692
-3.16%
Reuters·
SH
562050
-2.79%
SZ
002907
-0.40%
HK
03692
-3.16%

HANSOH PHARMA's stabilization price period ends, and the over-allotment option becomes invalid

HANSOH PHARMA - B announced that the stabilization period for the global offering ended on January 17. During this period, the stabilization agent did not take any stabilization actions. In addition, the over-allotment option was not exercised and has expired on the same day

AASTOCKS·
HK
03692
-3.16%
AASTOCKS·
HK
03692
-3.16%

Hong Kong Stocks Rise for 4th Session

Hong Kong stocks rose 71 points (0.3%) to 26,917, marking the fourth consecutive session of gains, driven by consumer stocks and supported by AI advancements in China. The IPO market is expected to remain strong in 2026. However, sentiment was affected by a dip in U.S. futures and caution ahead of China's December trade figures. Notable early movers included Nongfu Spring (+6.4%), Kuaishou Tech (+4.3%), Hansoh Pharma (+3.2%), and Chow Tai Fook (+1.9%).

Trading Economics·
HK
03692
-3.16%
HK
01929
-3.89%
Trading Economics·
HK
03692
-3.16%
HK
01929
-3.89%
© 2026 Longbridge｜Disclaimer